Eleven days administration of AZM551248 was associated with the first histological evidence of FD and also marked the first appearance of elevated TGFβ transcript, consistent with the detection of immuno-reactive TGFβ in activated fibroblasts [9], and in the plasma [15]. This evidence concerns the gene TGFB1 and Fabry disease.